Mobile

Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ meningococcal vaccine with or without co-administration of a licensed viral vaccine and Boostrix in female adolescents and young a...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-001876-13

Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ meningococcal vaccine with or without co-administration of a licensed viral vaccine and Boostrix in female adolescents and young adults

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

•To demonstrate non-inferiority of MenACWY-TT co-ad with a viral vaccine compared to MenACWY-TT alone with respect to GMTs for A, C, W-135 and Y. •To demonstrate the non-inferiority of a viral vaccine co-ad with MenACWY-TT compared to a viral vaccine alone in terms of HPV GMTs. •To demonstrate non-inferiority of MenACWY-TT co-ad with a viral vaccine and Boostrix compared to MenACWY-TT alone with respect to GMTs for A, C, W-135 and Y. •To demonstrate non-inferiority of a viral vaccine co-ad with MenACWY-TT and Boostrix compared to a viral vaccine co-administered with Boostrix in terms of HPV GMTs. •To demonstrate non-inferiority of Boostrix co-ad with MenACWY-TT and a viral vaccine compared to Boostrix co-administered with a viral vaccine in terms of anti-D and anti-T concentrations. •To demonstrate non-inferiority of Boostrix co-ad with MenACWY-TT and a viral vaccine compared to Boostrix co-administered with a viral vaccine with respect to GMCs to pertussis antigens.

Critère d'inclusion

  • Meningococcal Disease

Liens